Phase II single-arm study of palbociclib and cetuximab in anti-EGFR naïve patients with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer
While clinical benefit was observed with the combination, it did not meet its pre-specified endpoint for efficacy in patients with KRAS/NRAS/BRAF WT EGFR therapy-naïve mCRC patients. Clinicaltrials.gov Identifier: NCT03446157.
Authors
- Tammy Triglianos
- Mohamed E. Salem (ORCID: https://orcid.org/0000-0002-3661-6785)
- Ashwin Somasundaram (ORCID: https://orcid.org/0000-0003-3167-406X)
- Matthew J. Reilley (ORCID: https://orcid.org/0000-0002-4725-0459)
- Hanna K. Sanoff (ORCID: https://orcid.org/0000-0001-8679-4486)
- Autumn J. McRee (ORCID: https://orcid.org/0000-0002-0475-1579)
- Jonathan D Sorah (ORCID: https://orcid.org/0000-0002-2501-720X)
- Michael S. Lee (ORCID: https://orcid.org/0000-0001-8407-3423)
- Dominic T. Moore
Institutions
- University of North Carolina at Chapel Hill (US)
- Johnson & Johnson (United States) (US)
- Levine Cancer Institute (US)
- Springhouse (US)
- University of Virginia (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1093/oncolo/oyaf305
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- National Institutes of Health